A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)
Patologie
Stato
Autorizzato - In attesa di apertura
Codice studio
MK-2870-020-00/GOG-3101/ENGOT-cx20
Codice EudraCT
2023-508323-12
Sponsor/Promotore
Merck Sharp & Dohme corp
Tipologia
Sperimentale
Fase
III
Unità Operativa
Principal Investigator